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______________________________________________________________________________________ 
Abstract 
 The present study was conducted to investigate the effect of dietary silymarin on milk yield, milk fat, 
and certain blood parameters of dairy cattle. Silymarin is a naturally accepted hepatoprotectant that is used 
in the treatment of liver diseases in human beings, and has been tested in dairy cows during peripartum. 
Animals are subject to subclinical fatty liver. In the first part of the study, the silymarin (20 g/head/day) was 
supplemented to dairy cattle rations in the last 21 days (peripartum) of pregnancy. In the second part of 
study, silymarin was added to the rations of Holstein dairy cows for three weeks postpartum. A total of 40 
Holstein dairy cows at 2
nd
 lactation with 550-600 kg live weight and average body condition score of 3.5 were 
used. Dairy cows were randomly separated into two treatment groups (20 cows in each). The first group was 
control (no addition) and the second group was treatment (silymarin supplemented) group. Treatments 
significantly increased milk yield, but decreased milk protein. Postpartum bodyweight loss was significantly 
less in the silymarin group than in the control group. Differences in postprandial plasma triglyceride (TRG) 
and total cholesterol (TC) levels were found to be significant. Plasma alanine aminotransferase (ALT) and 
total protein (TP) values of the groups were also significantly different. As a result, it was observed that 
silymarin supplementation of the ration did not have side effects, and peak milk yields could be achieved 
earlier with silymarin treatment. Application of silymarin is believed to be useful. It was also observed that 
silymarin treatments speeded up the metabolic adaptation process of the dairy cows at the beginning of 
lactation. It was suggested that silymarin should be used in transition periods of dairy cattle.  
______________________________________________________________________________________ 
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Various metabolic problems are experienced through periparturient periods of dairy cattle. Dry matter 
(DM) intakes decrease during the last period of pregnancy and at the beginning of lactation. Together with 
negative energy balance, intense mobilization is experienced in body building scores (Drackley, 1999; Bobe 
et al., 2004; Oltenacu & Broom, 2010). The energy balance of high-yield cows is disrupted when the required 
energy is not supplied with their rations. Then, as a result of maladaptation to this negative energy balance, 
hepatic lipidosis (fatty liver) and ketosis-like metabolic diseases occur (Herdt, 2000; Mann et al., 2015). 
While the survival rate energy requirements of animals with different milk yields are the same, yield 
rate requirements may be different. This difference points out the significance of energy balance being 
provided through feeding in high-yield animals (Capper et al., 2008). In hepatic lipidosis cases, non-esterified 
fatty acid quantities increase and they are esterified to triglyceride through oxidation of hepatic fatty acids. 
Hepatic lipidosis increases the risk of ketosis, abomasum displacement, metritis, and immune system 
suppression, and reduces reproductive performance (Bobe et al., 2004). During the peripartum period, in 
addition to reduced dry matter intake and negative energy balance, intense metabolization of body building 
stones is experienced. In that period, hepatoprotective agents are used to prevent fat accumulation in the 
liver. Methionine, choline, propylene glycol, and glycerol were used as preservatives in the cattle during the 
studies and their therapeutic properties were discovered (MoaUem et al., 2007; Grummer,1993; Bertics & 
Grummer, 1999; Goff et al.,1996). Silymarin is a hepatoprotective agent that contains liver-protecting 
substances. It is a standard extract that is taken from Silybum marianum L. (milk thistle) seeds and is used in 
the treatment of human liver diseases with various aetiologies (Saller et al., 2001). Silymarin extract is a 
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complex structure composed of several flavonolignan isomers (Skottova et al., 2003). Silymarin has been 
used in herbal treatments for 2000 years.  
Today, it is commonly used in the protection and treatment of the liver (Morazzoni & Bombardelli, 
1995; Tamayo & Diamond, 2007). Improvements and increased functionality were observed in damaged 
livers with silymarin treatments (Leng, 1996; Fraschini et al., 2002). Silymarin influences cell permeability 
and has an antioxidant characteristic that prevents lipid peroxidation and membrane breakdown (Muriel & 
Mourelle, 1990; Mira et al., 1994; Fuchs et al., 1997). Such impacts of silymarin were reported by other 
researchers (Campose et al., 1989; Muriel & Mourelle, 1990; Mira et al., 1994). Skottova et al. (2003) 
reported that the polyphenol fraction of silymarin had positive effects on the lipoprotein profile of plasma and 
prevented fatty liver development in rats. Silymarin also significantly reduced serum gamma 
glutamyltranspeptidase, alanine transaminase (AST) and the aspartate transaminase levels of rats with liver 
damage (Wang et al., 1996).  
The present study was therefore conducted to investigate the effects of silymarin supplementation to 
dairy cattle rations in preventing negative energy balance-induced liver damage on serum blood parameters 
[calcium (Ca), glucose (GL), triglyceride (TRG), cholesterol (TC), phosphorus (P), ALT and AST, total protein 
(TP)], milk yield, and components of fat, protein, lactose.  
 
Materials and Methods 
A commercial dairy herd with 1700 lactating Holstein Friesian dairy cows located in Kayseri Province, 
Turkey, was used. The herd was housed in a free-stall barn, fed on total mixed rations (TMR), and milked 
twice daily. Silymarin was supplemented to rations of second parity Holstein dairy cows with three weeks to 
calving. In the second part of study, silymarin was added to the rations of Holstein dairy cows for three 
weeks postpartum. The cows had live weights between 555 and 600 kg. The cows were selected from those 
with an average body condition score (BCS) of 3.5. Two groups were formed with 20 cows each (a total of 
40 dairy cows were used). The first group was fed a regular ration (control). Together with the regular ration, 
silymarin extract was supplied to the second group orally, immediately after mixing with water to have 20 
g/head/day silymarin consumption.  
Animal feeds were supplied based on DM intake to have 20.77 kg feed per animal. Rations were 
prepared in accordance with the norms specified by National Research Council (NRC, 2001) for Holstein 
breed dairy cows with an average daily milk yield of 35 litres to meet their daily nutritional needs. Nutritional 
and chemical composition of the feeds supplied to animals are provided in Table 1 and the components of 
concentrate feed are listed in Table 2. The chemical composition of concentrate feed is provided in Table 3. 
 
 
Table1 Components and chemical composition of TMR 
 
Ingredients  Naturally/kg DM kg Ration DM% 
    
Corn silage 13.00 4.02 19.34 
Wheat straw 2.70 2.57 12.38 
Dry alfalfa 1.50 1.38 6.65 
Beet pulp 1.00 0.19 0.91 
Cattle milk feed (concentrated feed) 13.50 12.61 60.73 
Parameters Dry alfalfa Corn silage Beet pulp Wheat straw 
CP% 25.10 8.93 11.00 4.96 
CA% 9.08 4.28 4.48 7.56 
DM% 92.00 30.90 18.80 95.20 
CC% 1.98 3.22 2.00 1.63 
ADF% 28.60 28.00 23.30 49.10 
NDF% 39.20 45.20 45.50 73.20 
ME (Mcal/kg) 2.040 2.320 2.65 1.52 
     
Naturally (added to the ration), CP: crude protein (%of DM), CA: crude ash (% of DM), DM: dry matter (% of fresh), crude 
fat (% of DM), ADF: acid detergent fibre (% of DM), NDF: neutral detergent fibre (% of DM), ME: metabolizable energy 
(Mcal/kg DM) 
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Table 2 Components of concentrate feed supplied to animals  
 
Concentrated feed components Naturally, kg DM, kg Ration DM% 
    
Grain barley 2.73 2.67 22.06 
Soybean meal (46% CP) 3.48 3.24 27.00 
Soybean full-fat  0.65 0.6 5.00 
Kernel corn 1.56 1.48 12.23 
Kernel wheat 0.65 0.61 5.04 
Corn bran 0.32 0.30 2.47 
Wheat bran 0.65 0.60 5.00 
Molasses 0.45 0.39 3.22 
Cottonseed meal (30% CP) 0.26 0.24 2.00 
Bypass oil 0.32 0.31 2.56 
Marble powder 0.27 0.27 2.23 
Sunflower seed meal (37% CP) 1.17 1.10 9.09 
Salt 0.23 0.21 1.73 
DCP (dicalcium phosphate) 0.07 0.07 0.06 
Premixed* 0.01 0.01 0.08 
    
Naturally (added to the ration): vitamin-mineral premixed two kg of eating a ton. Mineral and vitamin content: vitamin A 
12,000,000 UI; vitamin D3 2,400,000 UI; vitamin E 50000 mg; vitamin K3 1000 mg; vitamin B1 600 mg; vitamin B2 2500 
mg; vitamin B6 150 mg; vitamin C 2000 mg; niacin 200000 mg; folic acid 2000 mg; biotin 200 mg; choline chloride 
100000mg; d l methionine 330 mg; iron 80000 mg; copper 15000 mg; manganese 50000 mg; cobalt 150 mg; zinc 
150000 mg; iodine 800 mg; selenium 150 mg 
 
 




(Declaration of manufacturer) 
Analysed results 
   
CP% 22 22.45 
DM% 88 93.42 
CA% 8 8.22 
CS% 12 8.74 
CF% - 3.64 
ME 2750 2785 
CP: crude protein (%of DM), DM: dry matter (% of fresh), CA: crude ash (% of DM), CC: crude cellulose (% of DM), CF: 
crude fat (% of DM), ME: metabolizable energy (Mcal/kg DM) 
 
Analyses of DM, CA, CP, CC, and CF contents of feed sources were carried out in accordance with 
AOAC (1998). Acid detergent fibre (ADF) and neutral detergent fibre (NDF) analyses were carried out in 
accordance with Van Soest et al. (1991), and metabolic energy (ME) was calculated by the equation 
proposed by Robinson et al. (2004):  
 
ME = 14.03-(0.01386 x CF%)-(0.1018 x CA%). 
 
From the beginning of the experiment, bodyweights were measured weekly with a digital balance (± 
500 g). 
Daily milk yields of each animal were recorded to a herd management programme separately from the 
Dairymaster milking system. Then, milk yield per animal was taken from the system. A total of 40 milk 
samples were taken and subjected to Foss MilkoScan FT1 device (Milkoscan, Foss, Denmark) without 
waiting for chemical analysis. 
At the beginning and end of the study, 80 blood samples were taken from the vena jugularis four hours 
after feeding. The blood samples were placed 10 ml tubes containing heparin, and centrifuged at 3000 rpm 
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for 10 minutes to obtain blood plasma. The resultant plasma samples were kept in a deep freezer at -20 °C 
until the time of analysis. 
Plasma samples were then thawed at room temperature and subjected to ALT, AST, TP, glucose, 
triglyceride, and cholesterol analyses at the central laboratories of Erciyes University Medical Faculty. For 
metabolite analysis of the plasma samples, an autoanalyser with commercial kits (Abbott Diagnostics, 
Architect, USA) was used. 
The following mathematical model was used in experiments:  
 
Yij = µ + αi + εij 
 
Where: Yij = observation value for j
th
 replication of i
th
 treatment  
μ = general population mean  
αi = effect of i
th
 treatment 
eij = random error for j
th
 replication of i
th
 treatment  
 
Significance level was set as P <0.05. Results were expressed as mean ± standard error. All analyses 
were carried out with the GLM module of SAS software. 
 
Results 
The differences in prenatal and postnatal first-week bodyweights were not found to be significant 
(Table 4). However, bodyweights of the groups were significant in the second and third week (P <0.05). 
 
 
Table 4 Body weights at the beginning and the end of experiment and milk components 
 
Parameters Control Silymarin SEM P 
     
Prenatal BW 564.15 564.95 2.624 0.881 
First week BW 518.85 519.95 2.426 0.824 
Second week BW 493.00 514.55 2.901 <0.001 
Third week BW 488.00 514.55 3.142 <0.001 
Milk yield,% 27.30 30.50 0.492 <0.001 
Milk fat,% 3.54 3.46 0.013 0.003 
Milk protein,% 3.72 3.45 0.027 <0.001 
Milk lactose,% 4.94 4.94 0.013 0.939 
     
SEM: standard error of mean; P: probability; BW: bodyweight (kg) 
 
 
There was less postnatal weight loss in the silymarin treated cows than the control group. There were 
significant differences in the milk yields of the control and the treatment group (P <0.001). The silymarin 
group had higher milk yield than the control group. On the other hand, milk fat and protein contents were 
higher in the control group than in the treatment group. The differences in milk fat and protein contents were 
found to be significant, but the differences in milk lactose contents were not (P = 0.939). 
The values obtained from the blood samples in the initial stage of the study are provided in Table 5. 
The differences among the blood parameters of the groups were not found to be significant. 
Compared with prenatal blood samples, the glucose concentration of postnatal samples decreased. 
This decrease was lower in the silymarin group. The differences in plasma glucose contents of the groups 
were not found to be significant (P = 0.036). While there were significant differences in the concentrations of 
plasma TRG (P = 1.000) and plasma cholesterol (P = 0.680), the silymarin group had higher TRG and 
cholesterol concentrations than the control treatment. However, it was not statistically significant. While the 
effects of silymarin treatments on AST enzyme activity were not significant (P = 0.416), (P = 0.397), 
increasing ALT enzyme activities were observed with silymarin treatments (P <0.001). The prenatal 
treatment group had lower protein concentrations than the control group, but these differences were not 
found to be significant (P = 0.085). However, postnatal plasma protein concentrations were higher in the 
treated group (P <0.001). The differences in prenatal Ca and P concentrations of plasma samples of the 
silymarin group were not significant. On the other hand, lower decreases were observed in the Ca and P 
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concentrations of postnatal plasma samples of the treatment group, but the differences were not found to be 
significant (P = 0.844), (P = 0.283). 
 
 






     
GL (mg/dL) 53.40 46.65 1.627 0.036 
TRG (mg/dL) 31.65 31.65 0.533 1.000 
TC (mg/dL) 101.55 99.65 2.264 0.680 
AST (U/l) 63.25 60.15 1.878 0.416 
ALT (U/l) 27.45 28.00 1.013 0.790 
TP (mg/dL) 7.51 7.11 0.117 0.085 
Ca (mg/dL)  14.75 13.55 1.274 0.644 





GL (mg/dL) 41.15 45.65 1.236 0.068 
TRG (mg/dL) 14.15 26.65 1.100 <0.001 
TC (mg/dL) 78.55 98.15 2.333 <0.001 
AST (U/l) 59.75 56.50 1.890 0.397 
ALT(U/l) 30.45 38.00 1.179 <0.001 
TP (mg/dL) 6.26 7.11 0.132 <0.001 
Ca (mg/dL) 12.65 13.15 1.244 0.844 
P (mg/dL) 5.25 6.60 0.622 0.283 
     
SEM: standard error of means; P: probability; GL: glucose (mg/dL); TRG: triglyceride (mg/dL); TC: total cholesterol 
(mg/dL); AST: aspartate amino transferase enzyme (U/l); ALT: alanine amino transferase enzyme (U/l); TP: total protein 




Experiments were conducted in two phases, namely prenatal and postnatal. In comparison with the 
control treatment, bodyweight, milk yield, differences in parameters were observed in serum blood TRG, TC, 
ALT, AST, and TP. There were no problems with regard to health of animals in both prenatal and postnatal 
periods. Bodyweight losses were higher in the control group than in the treatment group (Gerloff et al., 
1986). Body weight measurements at the end of the third
 
week revealed that weight loss was higher in the 
control group than in treatment group. Previous studies also reported body weight losses in early lactation 
period (Ingvartsen et al., 2003; Meijer, 2010). However, weight loss was lower in the silymarin-treated group. 
Higher weight losses in the control group than the treatment group could be related to hepatic lipidosis 
and resultant malfunction of the liver (Gerloff et al., 1986). Lucy et al. (2001) indicated that total milk yield 
could be improved with proper feeding throughout the transition period. Silymarin reduced the negative 
conditions experienced in transition to metabolic adaptation at the beginning of lactation and thus improved 
the milk yields. Although there are not any concrete evidences that silymarin treatments improved milk 
yields, similar findings were reported in previous studies (Garavaglia et al., 2015). Besides antioxidant 
impacts, silymarin was reported to have hepatoprotective effects, and to prevent fat accumulation in the liver 
(Tedesco et al., 2004). In terms of the plasma glucose levels, significant differences were not observed 
between prenatal and postnatal values. The decrease in plasma glucose levels was lower in silymarin group 
than in control group. 
The decrease in insulin concentration might have resulted in reduced serum glucose concentration. 
With silymarin treatments, plasma insulin concentration may increase fatty acid oxidation in the pancreas. 
Stimulation of insulin segregation from pancreas β-cells by glucose depends on the availability of fatty acids 
(Stein et al., 1996). Fatty acid oxidation in β-cells may increase in cows fed with silymarin-supplemented 
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rations and reduced availability of fatty acids may cause an increase in insulin segregation.  On the other 
hand, silymarin supplementation may alter peripheral glucose metabolism and insulin sensitivity, and thus 
influence glucose metabolism. It was observed that silymarin influenced not only β-oxidation of fatty acids, 
but also glucose metabolism. Silymarin treatments increased glucose oxidation and storage in patients with 
type II diabetes (Mingrona et al., 1999; Tedesco et al., 2004). Present plasma glucose quantities comply with 
those of earlier reports (Mehta & Gangwar, 1985; Karagül et al., 1999; Polat et al., 2002). 
It has been reported in previous studies that silymarin reduces triglyceride synthesis in liver (Skottova 
& Kreeman, 1998) and activates fatty acid β-oxidation (Valenzuela & Garrido, 1994). However, in another 
study, less reduction was reported in the TRG quantities of the silymarin group than the control group. 
Current plasma triglyceride levels do not comply with those of earlier reports (Mourelle et al., 1989; 
Valenzuela & Garrido, 1994; Skottova & Kreeman, 1998). 
Although there were no significant differences in TC and TRG concentrations, there was a numerical 
decrease in TC concentrations of treatment group than the control. 
Plasma cholesterol levels were similar to earlier findings (Haddad et al., 2011). Haddad et al. (2011) 
reported that silibinin extracts (200 ml/kg) in a high-fat liquid diet decreased the cholesterol levels of rats, but 
the differences were not significant. Sobolova et al. (2006) reported increased serum cholesterol levels of 
rats with silymarin extract treatments. In another similar study, silymarin significantly reduced liver cholesterol 
levels (Skottova et al., 2003; Sobolova et al., 2006). The ALT and AST exhibit quite high activity in acute or 
chronic liver damage, and such activity can be identified in serum (Turgut, 2000). Fatty liver syndrome in 
lactating cows may reduce the appetite (Cebra et al., 1997), and ketosis at early lactation may increase AST 
enzyme activity (Steen, 2001). This may be used as a bio-indicator for possible liver damage (Kauppinen, 
1984; Meyer & Harvey, 1988). Contrary to AST activity, ruminants do not have high ALT activity. Changes in 
serum ALT activities thus cannot be clearly identified in liver damage (Forenbacher, 1993). There are 
distinctive irregular and slight changes in AST and gamma glutamyl transferase enzyme activities in 
pregnancy and early lactation periods. On the other hand, ALT activities decrease distinctively during the 
seventh and eighth months of pregnancy and at the beginning of lactation (Tainturier et al., 1984). In the 
present study, differences in AST activities of treatment and control group were not found to be significant. 
The decrease in AST activity may be related to silymarin supplementation. As indicated, an increase in 
serum AST activity may be used for sub-clinic diagnosis of possible liver damage (Kauppinen, 1984; Meyer 
& Harvey, 1988). Therefore, different silymarin levels may be experimented with for various periods to 
elucidate these effects. The present findings may also provide significant contributions for researchers that 
are studying the protective effects of silymarin on liver. In the present study, significant differences were 
observed only in postnatal ALT activities. These differences had resulted from transition from feed 
adaptation to lactation periods. Stojević et al. (2005), reported significant increases in serum ALT activities in 
early lactation compared with the control treatment. In the present study, silymarin supplementation 
increased ALT activities, but such changes were not considered sufficient to be related to liver damage. 
 
Conclusion 
It was concluded that silymarin supplementation to feed rations did not have negative side effects. It 
was also observed that silymarin supplementations might speed up the transition to metabolic adaptation of 
dairy cows at the beginning of lactation, and might result in earlier achievement of peak milk yield. Various 
silymarin doses could be applied to observe the impacts of silymarin supplementation on tissues, especially 
on liver. In further studies, the effects of silymarin treatments on the metabolic profile could be studied in 
detail. The present findings might contribute to those future studies on silymarin supplementation. 
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